Alex Hamilton

2 months ago | nature.com | Kelsey Swingle |Alex Hamilton |Ajay S. Thatte |Amanda Murray |Emily Han |Xuexiang Han | +2 more

Correction to: Nature https://doi.org/10.1038/s41586-024-08291-2 Published online 11 December 2024In the version of the article initially published, in Fig. 2b, the x-axis label “µg β2-GPI per µg lipid” has now been amended to “µg ApoE per µg lipid”. In Fig. 2d, the x-axis label “µg ApoE per µg lipid” has now been amended to “µg β2-GPI per µg lipid”. In the key for Figs. 3e–j, “LNP + LNP 55” was incorrect and has now been amended to “LPS + LNP 55”.

Dec 11, 2024 | nature.com | Kelsey Swingle |Alex Hamilton |Ajay S. Thatte |Amanda Murray |Emily Han |Xuexiang Han | +2 more

AbstractPre-eclampsia is a placental disorder that affects 3–5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide1,2. With no drug available to slow disease progression, engineering ionizable lipid nanoparticles (LNPs) for extrahepatic messenger RNA (mRNA) delivery to the placenta is an attractive therapeutic option for pre-eclampsia.